Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Payables (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Payables for 16 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 32.49% year-over-year to $11.2 million, compared with a TTM value of $11.2 million through Dec 2025, down 32.49%, and an annual FY2025 reading of $11.2 million, down 32.49% over the prior year.
  • Payables was $11.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $9.1 million in the prior quarter.
  • Across five years, Payables topped out at $16.6 million in Q4 2024 and bottomed at $2.3 million in Q2 2022.
  • Average Payables over 5 years is $6.7 million, with a median of $4.9 million recorded in 2022.
  • The sharpest move saw Payables tumbled 49.63% in 2021, then skyrocketed 272.2% in 2023.
  • Year by year, Payables stood at $2.8 million in 2021, then surged by 43.61% to $4.0 million in 2022, then surged by 272.2% to $14.8 million in 2023, then grew by 12.15% to $16.6 million in 2024, then tumbled by 32.49% to $11.2 million in 2025.
  • Business Quant data shows Payables for CPRX at $11.2 million in Q4 2025, $9.1 million in Q3 2025, and $5.5 million in Q2 2025.